ARS Pharmaceuticals (SPRY) Net Cash Flow Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | ARS Pharmaceuticals | 585.25 Mn | 384.28 Mn | - | -55.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.17% |
| Dec 31, 2025 | -263.44% |
| Sep 30, 2025 | 164.50% |
| Jun 30, 2025 | 160.25% |
| Mar 31, 2025 | 26.81% |
| Dec 31, 2024 | 6.91% |
| Sep 30, 2024 | 105.18% |
| Jun 30, 2024 | -162.21% |
| Mar 31, 2024 | 87.80% |
| Dec 31, 2023 | -93.97% |
| Sep 30, 2023 | -704.69% |
| Jun 30, 2023 | 508.91% |
| Mar 31, 2023 | -1,461.70% |
| Dec 31, 2022 | 42.61% |
| Sep 30, 2022 | 87.69% |
| Jun 30, 2022 | 47.51% |
| Mar 31, 2022 | 36.48% |
| Dec 31, 2021 | -50.24% |
| Sep 30, 2021 | -152.61% |
| Jun 30, 2021 | -323.84% |